| Literature DB >> 30514321 |
Sang-Nee Tan1, Sai-Peng Sim2, Alan S B Khoo3.
Abstract
BACKGROUND: Oxidative stress is known to be involved in most of the aetiological factors of nasopharyngeal carcinoma (NPC). Cells that are under oxidative stress may undergo apoptosis. We have previously demonstrated that oxidative stress-induced apoptosis could be a potential mechanism mediating chromosome breakages in nasopharyngeal epithelial cells. Additionally, caspase-activated DNase (CAD) may be the vital player in mediating the chromosomal breakages during oxidative stress-induced apoptosis. Chromosomal breakage occurs during apoptosis and chromosome rearrangement. Chromosomal breakages tend to cluster in certain regions, such as matrix association region/scaffold attachment region (MAR/SAR). We hypothesised that oxidative stress-induced apoptosis may result in chromosome breaks preferentially at the MAR/SAR sites. The AF9 gene at 9p22 was targeted in this study because 9p22 is a deletion site commonly found in NPC.Entities:
Keywords: AF9 gene; Apoptosis; H2O2; MAR/SAR; NPC; Oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 30514321 PMCID: PMC6278157 DOI: 10.1186/s12867-018-0116-5
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
MAR/SARs predicted within the AF9 gene by using MRS
| Predicted MAR/SAR | AWWRTAANNWWGNNNC (16 bp) | Nucleotide position | AATAAYAA (8 bp) | Nucleotide position | Distance (bp) | Location in exon/intron |
|---|---|---|---|---|---|---|
| 1 | ATAATAATAAAAGCCC (C) | 916–931 | AATAATAA (C) | 915–922 | Overlap | Intron 1 |
| 2 | ATAGTAAGGATGGCTG (W) | 5636–5651 | AATAATAA (W) | 5694–5701 | 42 | Intron 2 |
| 3 | AAAATAACAAAGGAAG (W) | 10,555–10,570 | AATAACAA (W) | 10,561–10,568 | Overlap | Intron 2 |
| 4 | AATATTATTATGGGTC (W) | 26,366–26,381 | AATAATAA (W) | 26,420–26,427 | 38 | Intron 2 |
| 5 | AAAGTAAACTGGAAAC (C) | 47,851–47,866 | AATAACAA (W) | 47,627–47,634 | − 216 | Intron 2 |
| 6 | AAAATAATAATAATAC (W) | 56,224–56,239 | AATAATAA (W) | 56,227–56,234 | Overlap | Intron 2 |
| 7 | AAAATCATCTTGGGAC (W) | 94,045–94,060 | AATAACAA (W) | 93,895–93,902 | − 142 | Intron 2 |
| 8 | AAAATAATAAAAACCC (C) | 108,633–108,648 | AATAATAA (C) | 108,635–108,642 | Overlap | Intron 2 |
| 9-1 | ATAATAACATTTTACC (C) | 112,369–112,384 | AATAATAA (C) | 112,368–112,375 | Overlap | Intron 2 |
| 9-2 | AAAATAATAATTGTAC (C) | 113,269–113,284 | AATAATAA (C) | 113,271–113,278 | Overlap | Intron 2 |
| 10 | ATTGGAATGTAGAAAC (W) | 117,722–117,737 | AATAACAA (W) | 117,606–117,613 | − 108 | Intron 2 |
| 11-1 | AATATAATCTAATTGC (W) | 128,593–128,608 | AATAACAA (C) | 128,355–128,362 | − 230 | Intron 2 |
| 11-2 | AAAATAAGTTTCCAGC (W) | 129,838–129,853 | AATAACAA (C) | 129,941–129,948 | 87 | Intron 2 |
| 12 | ATAATAATAAAATCAC (W) | 136,176–136,191 | AATAATAA (W) | 136,182–136,189 | Overlap | Intron 2 |
| 13 | AATATAATGAATATCC (C) | 139,927–139,942 | AATAATAA (C) | 139,902–139,909 | − 17 | Intron 2 |
| 14 | TTTATAAACTTGTTTC (C) | 151,672–151,687 | AATAATAA (W) | 151,857–151,864 | 169 | Intron 2 |
| 15 | AAAATAAAAAAGAGCT (C) | 158,541–158,556 | AATAATAA (W) | 158,593–158,600 | 46 | Intron 2 |
| 16 | AAAATAATAAATACGC (W) | 170,523–170,538 | AATAATAA (W) | 170,529–170,536 | Overlap | Intron 3a |
| 17-1 | ATAATAAATATGAATA (W) | 178,638–178,653 | AATAATAA (W) | 178,634–178,641 | Overlap | Intron 3b |
| 17-2 | AAAAGAACTAAGGTAC (W) | 179,378–179,393 | AATAATAA (W) | 179,140–179,147 | − 230 | Intron 3b |
| 18 | AAGGTAAATTAGCAGC (W) | 182,936–182,951 | AATAATAA (C) | 183,173–183,180 | 221 | Intron 3b |
| 19 | ATTATAAGAAAAATTC (W) | 191,065–191,080 | AATAATAA (W) | 191,323–191,330 | 242 | Intron 3b |
| 20-1 | AAAATAAGAAAACATC (W) | 194,333–194,348 | AATAATAA (W) | 194,511–194,518 | 162 | Intron 3b |
| 20-2 | AATATAAAATTGCAAG (W) | 195,275–195,290 | AATAATAA (C) | 195,198–195,205 | − 69 | Intron 3b |
| 21 | AAAATAATAAAGCCAT (W) | 200,768–200,783 | AATAATAA (W) | 200,774–200,781 | Overlap | Intron 3b |
| 22-1 | ATAATAATAATAATAC (W) | 215,365–215,380 | AATAATAA (W) | 215,368–215,375 | Overlap | Intron 4 |
| 22-2 | AAAATAAAACTGACTC (C) | 215,781–215,796 | AATAACAA (C) | 215,941–215,948 | 144 | Intron 4 |
| 23 | ATAATAATAATGAAAG (C) | 227,849–227,864 | AATAATAA (C) | 227,848–227,855 | Overlap | Intron 4 |
| 24-1 | ATAATAAGTTATAGGC (W) | 236,299–236,314 | AATAATAA (W) | 236,308–236,315 | Overlap | Intron 4 |
| 24-2 | AAAATAACAAAATGTC (W) | 237,605–237,620 | AATAACAA (W) | 237,611–237,618 | Overlap | Intron 4 |
| 24-3 | AATGTAAGCAATATCC (W) AAAGTATTGTAGACCC (C) | 237,817–237,832 | AATAATAA (W) | 238,001–238,008 | 168 | Intron 4 |
| 24-4 | TATATAATAAAGTGAC (C) | 238,794–238,809 | AATAATAA (W) | 239,050–239,057 | 240 | Intron 4 |
| 25-1 | ATAATAATGAAGAAAG (C) | 246,610–246,625 | AATAATAA (C) | 246,588–246,595 | − 14 | Intron 4 |
| 25-2 | ATTGTAATATTGATTG (C) | 247,587–247,602 | AATAACAA (C) | 247,561–247,568 | − 18 | Intron 4 |
| 26-1 | AAAGTAAATAAAAAAC (W) | 251,265–251,280 | AATAATAA (C) | 251,344–251,351 | 63 | Intron 4 |
| 26-2 | AATGAAAGGAAGAGCC (W) | 252,636–252,651 | AATAATAA (C) | 252,893–252,900 | 241 | Intron 4 |
| 27 | ATAATAAACTACCATC (W) | 262,931–262,946 | AATAATAA (W) | 262,940–262,947 | Overlap | Intron 7 |
| 28-1 | AATATAATCTTGAACG (C) | 265,612–265,627 | AATAATAA (C) | 265,768–265,775 | 140 | Intron 7 |
| 28-2 | AAAATAAAAATATGCC (C) | 266,963–266,978 | AATAATAA (C) | 267,133–267,140 | 154 | Intron 7 |
| 28-3 | AAGATAAATTAGGTCC (C) | 267,317–267,332 | AATAATAA (C) | 267,569–267,576 | 236 | Intron 7 |
| 29 | AAAAAAAAATTGTAAC (W) | 273,593–273,608 | AATAACAA (W) | 273,528–273,535 | − 57 | Intron 9 |
Nucleotide positions of the MRSs with their sequence composition, relative orientation (C: Crick strand and W: Watson strand), distance between the two sequence elements and location of the MRSs in the exon or intron of the AF9 gene are shown. A negative distance indicates that 8 bp sequence element precedes the 16 bp sequence element
Fig. 1Distribution of potential MAR/SAR sites predicted in the AF9 gene. The AF9 genomic map from nucleotide positions 601–281,480 is illustrated above [EMBL:ENSG00000171843]. The locations of exons 1 to 10 and BamH I (B) restriction sites are shown. Green boxes indicate the two patient BCRs reported in the previous study. These two patient BCRs were denominated as BCR1 and BCR2 [28]. Yellow boxes indicate the two MAR/SARs that were biochemically identified by Strissel and co-workers. These two MAR/SARs were designated as SAR1 and SAR2 [28]. Yellow arrows represent the potential MAR/SAR sites predicted by MRS in our study. Clusters of more than one MRS within close proximity are regarded as a single potential MAR/SAR site. Three MRSs were found in SAR1 (MAR 24-2, 24-3, 24-4). One MRS (MAR 27) has been predicted next to the SAR2. Based on the in silico prediction of MAR/SAR, a SAR region (contains MAR/SAR) and a non-SAR region (does not contain MAR/SAR) were determined to be the regions of study
Fig. 2Cleavage frequencies of the AF9 SAR and non-SAR regions in H2O2-treated NP69 cells. a Representative gel pictures showing the IPCR results of the AF9 gene in H2O2-treated NP69 cells: i SAR region, ii Non-SAR region. NP69 cells were either untreated (lanes 2–7) or treated with 100 µM of H2O2 for 16 h (lanes 8–13). The cells were harvested for gDNA extraction and nested IPCR. For each cell sample, six IPCR replicates (R1–R6) were prepared. The side brackets show the IPCR bands derived from the cleavages of the AF9 gene. M: 100 bp DNA ladder. N: Negative control for IPCR. b AF9 cleavage frequency detected in NP69 cells. Data are representative of three independent experiments. Each experiment consisted of 1–2 sets of IPCR. Each set of IPCR was performed in 5–8 IPCR replicates per cell sample. The results are presented as medians with IQRs. *P < 0.05; NS: no significant difference (Mann–Whitney U test)
Fig. 3Cleavage frequencies of the AF9 SAR and non-SAR regions in H2O2-treated HK1 cells. a Representative gel pictures showing the IPCR results of the AF9 gene in H2O2-treated HK1 cells: i SAR region, ii non-SAR region. HK1 cells were either untreated (lanes 2–6) or treated with 50 µM of H2O2 for 8 h (lanes 7–11). The cells were harvested for gDNA extraction and nested IPCR. For each cell sample, five IPCR replicates (R1–R5) were prepared. The side brackets show the IPCR bands derived from the cleavages of the AF9 gene. M: 100 bp DNA ladder. N: Negative control for IPCR. b AF9 cleavage frequency detected in HK1 cells. Data are representative of two independent experiments. Each experiment consisted of 1–2 sets of IPCR. Each set of IPCR was performed in 5–6 IPCR replicates per cell sample. The results are expressed as medians with IQRs. *P < 0.05; NS: no significant difference (Mann–Whitney U test)
Repeat elements in the AF9 SAR and non-SAR regions predicted by CENSOR program
| Nucleotide position | Predicted repeat elements | |||
|---|---|---|---|---|
| From | To | Name | Class | |
| SAR region | 236,920 | 236,987 | TWIFB1 | DNA/hAT |
| 237,423 | 237,476 | MER20 | DNA/hAT | |
| 237,491 | 237,548 | hAT-80_HM | DNA/hAT | |
| 237,594 | 237,636 | CR1-8_HM | NonLTR/CR1 | |
| 237,637 | 237,719 | L1ME4A | NonLTR/L1 | |
| 238,883 | 238,925 | GYPSY16-I_AG | LTR/Gypsy | |
| 239,516 | 239,716 | MIR | NonLTR/SINE | |
| 239,786 | 239,871 | ZAPHOD | DNA | |
| 241,267 | 241,318 | Polinton-1_XT | DNA/Polinton | |
| 241,475 | 241,555 | Hoyak1 | DNA/hAT | |
| 241,769 | 241,847 | L4 | NonLTR/RTEX | |
| 242,176 | 242,276 | ATCOPIA38_I | LTR/Copia | |
| 242,849 | 242,893 | BGLII_LTR | ERV/ERV2 | |
| 242,989 | 243,024 | L1-1_ET | NonLTR/L1 | |
| 243,397 | 243,483 | ERV1-4-EC_I | ERV/ERV1 | |
| 244,480 | 244,530 | hATw-2_SP | DNA/hAT | |
| 244,901 | 245,043 | CHARLIE7 | DNA/hAT | |
| 245,627 | 245,728 | ERE2_EH | Interspersed_Repeat | |
| Non-SAR region | 71,936 | 71,999 | BEL1_MH-I | LTR/BEL |
| 72,081 | 72,368 | AluJr4 | NonLTR/SINE/SINE1 | |
| 72,447 | 72,695 | AluJ | Interspersed_Repeat | |
| 73,459 | 73,707 | MIR | NonLTR/SINE | |
| 73,708 | 73,761 | TE-X-4_DR | Interspersed_Repeat | |
| 74,030 | 74,304 | AluJb | NonLTR/SINE/SINE1 | |
| 74,895 | 74,998 | CHARLIE5 | DNA/hAT | |
| 75,006 | 75,169 | CHARLIE5 | DNA/hAT | |
| 75,192 | 75,466 | AluJr | NonLTR/SINE/SINE1 | |
The AF9 SAR region is located at coordinates 236,059 to 246,292 [Ensembl:ENSG00000171843]. The nucleotide position, name and class of the predicted repeat elements are shown. The region amplified by the reverse primer (AF9 236,211 R) is from coordinates 236,059 to 236,211 while the region amplified by the forward primer (AF9 245,507 F) is from coordinates 245,507 to 246,292. The amplified SAR region contains one repeat element, namely ERE2_EH (at coordinates 245,627–245,728). The AF9 non-SAR region is located at coordinates 71,116 to 75,277 [Ensembl:ENSG00000171843]. The nucleotide position, name and class of the predicted repeat elements are shown. The region amplified by the reverse primer (AF9 71,282 R) is from coordinates 71,116 to 71,282 while the region amplified by the forward primer (AF9 74,494 F) is from coordinates 74,494 to 75,277. The amplified non-SAR region contains three repeat elements, namely two CHARLIE5 (at coordinates 74,895–74,998 and 75,006–75,169) and one AluJr (at coordinates 75,192–75,466)
Fig. 4The repeat elements identified within the AF9 SAR and the non-SAR regions. a The SAR region. The SAR region which is bordered by two BamH I sites is 10.2 kb in length (from coordinates 236,059 to 246,292). Green box represents the previously identified patient BCR which is indicated as BCR1. Yellow box shows the previously experimentally isolated MAR/SAR which is indicated as SAR1 [28]. Yellow arrows represent the potential MAR/SAR sites predicted by MRS in the present study. Green and blue arrows represent the primers used in the first and second rounds of nested IPCR, respectively. Black boxes show the repeat elements predicted by CENSOR program. BamH I (B), Kpn I (K) and Nde I (N) restriction sites are shown. b The non-SAR region. The non-SAR region which is bordered by two BamH I sites is 4.2 kb in length (from coordinates 71,116 to 75,277). Green and blue arrows represent the primers used in the first and second rounds of nested IPCR, respectively. Black boxes represent the repeat elements identified by using CENSOR program. BamH I (B), Hind III (H) and Xba I (X) restriction sites are shown
Fig. 5Caspase-3 inhibitor abolishes H2O2-induced cleavages within the AF9 SAR region. a Representative gel pictures showing the IPCR analysis of the AF9 SAR region in H2O2-treated HK1 cells: i without CI pre-treatment ii with CI pre-treatment. HK1 cells were left untreated or pre-treated with 50 µM of Z-DEVD-FMK for 1 h. The cells were then either untreated (lanes 2–7) or treated with 50 µM of H2O2 for 8 h (lanes 8–13). Genomic DNA was extracted and modified for nested IPCR. For each cell sample, six IPCR replicates (R1–R6) were prepared. The side brackets show the IPCR bands derived from the cleavages of the AF9 gene. M: 100 bp DNA ladder. N: Negative control for IPCR. b Cleavage frequency of the AF9 SAR region detected in HK1 cells. Data are representative of two independent experiments. Each experiment consisted of 1–2 sets of IPCR. Each set of IPCR was performed in 5–6 IPCR replicates per cell sample. The results are expressed as medians with IQRs. *P < 0.05 (Mann–Whitney U test)
Fig. 6Caspase-3 inhibitor shows no effect on reducing cleavages within the AF9 non-SAR region. a Representative gel pictures showing the IPCR analysis of the AF9 non-SAR region in H2O2-treated HK1 cells: i without CI pre-treatment ii with CI pre-treatment. HK1 cells were left untreated or pre-treated with 50 µM of Z-DEVD-FMK for 1 h. The cells were then either untreated (lanes 2–7) or treated with 50 µM of H2O2 for 8 h (lanes 8–13). Genomic DNA was extracted and modified for nested IPCR. For each cell sample, six IPCR replicates (R1–R6) were prepared. The side brackets show the IPCR bands derived from the cleavages of the AF9 gene. M: 100 bp DNA ladder. N: Negative control for IPCR. b Cleavage frequency of the AF9 non-SAR region detected in HK1 cells. Data are representative of two independent experiments. Each experiment consisted of 5–7 IPCR replicates per cell sample. The results are expressed as medians with IQRs. NS: No significant difference (Mann–Whitney U test)
Breakpoints identified within the AF9 SAR region in H2O2-treated cells
| Cell line treated with H2O2 | Breakpoint | Remarks |
|---|---|---|
| NP69 | 245,566 | This chromosome break was detected within the |
| 245,591 | This chromosome break was detected within the | |
| 245,645 | This breakpoint is 33 nucleotides different from that identified in an ALL patient (at coordinate 245,612) [GenBank:AM050804] | |
| 245,659 | This breakpoint is 47 nucleotides different from that identified in an ALL patient (at coordinate 245,612) [GenBank:AM050804] | |
| 245,711 | ||
| 245,730 | ||
| 245,804 | ||
| 245,817 | ||
| 245,826 | ||
| 245,842 | ||
| 245,959 | ||
| 245,970 | ||
| 246,089 | ||
| HK1 | 245,560 | This chromosome break was detected within the |
| 245,634 | This breakpoint is 22 nucleotides different from that identified in an ALL patient (at coordinate 245,612) [GenBank:AM050804] | |
| 245,681 | This breakpoint is 69 nucleotides different from that identified in an ALL patient (at coordinate 245,612) [GenBank:AM050804] | |
| 245,755 | ||
| 245,949 |
The nucleotide positions of the chromosome breaks identified within the AF9 SAR region were mapped according to the AF9 sequence retrieved from Ensembl database [EMBL:ENSG00000171843]
Fig. 7The positions of H2O2-induced chromosome breaks within the AF9 SAR region. a The AF9 genomic map from nucleotide positions 601–281,480 [EMBL:ENSG00000171843] [26]. Black vertical lines represent the locations of exons 1–10. Green boxes show the two previously identified patient BCRs, namely BCR1 and BCR2 [28]. Yellow boxes show the two MAR/SARs which were extracted experimentally in the previous study. These two MAR/SARs were indicated as SAR1 and SAR2 [28]. BamH I (B) restriction sites are shown. Yellow arrows represent the potential MAR/SAR sites predicted by MRS in our study. b The AF9 SAR region (10.2 kb). BamH I (B), Kpn I (K) and Nde I (N) restriction sites are shown. Green and blue arrows represent the primers used in the first and second rounds of nested IPCR, respectively. c Breakpoints mapped in H2O2-treated cells. Red and green vertical lines show the breakpoints identified in H2O2-treated NP69 and HK1 cells, respectively. All the chromosome breaks were mapped within BCR1 which is bordered SAR1 and SAR2. Blue box represents the AF9 region (at coordinates 245,252–245,612) that was previously reported to translocate with the MLL gene resulting in the formation of the MLL-AF9 fusion gene in an ALL patient [GenBank:AM050804]